2022-2029 年全球前列腺癌诊断市场

市场动态

前列腺癌诊断领域增加的研发计划和最近的监管批准正在推动市场增长。

诊断测试的不断进步以及政府为提高人们对癌症的认识而不断努力，预计将推动市场的增长。

前列腺癌诊断的持续进步正在推动全球市场增长。主要参与者推出的一些新测试包括：

2022 年 3 月，美国 FDA 批准了诺华公司生产的 Lu-PSMA-617。这是一种治疗前列腺癌的放射性药物疗法。

2020 年 8 月，Garnet Health 医疗中心提供创新技术以提高帮助早期诊断和治疗前列腺癌的能力。

2019 年 12 月 29 日，Anixa Biosciences, Inc. 宣布推出利用人工智能 (AI)、流式细胞术和液体活检技术检测前列腺癌的 Cchek 前列腺癌确认测试 (Cchek PCC)。在某些患者中，该测试的可用性可以减少对诊断前列腺癌患者的昂贵和侵入性活检程序的需求。

2019 年 9 月，伦敦玛丽女王大学的一项研究发现，一种新的、简单的血液检测可以有效且准确地检测出侵袭性前列腺癌的存在。结合目前的前列腺特异性抗原 (PSA) 测试，这项新测试可以帮助男性避免不必要的侵入性活检、过度诊断和过度治疗。一项新的前列腺癌检测（Angle plc 的 Parsortix 系统）可检测离开原始肿瘤、进入血液并扩散到全身的早期癌细胞或循环肿瘤细胞 (CTC)。 2019 年 7 月，MDNA Life Sciences 推出了 Mitomic Prostate Test (MPTTM)，这是世界上用于确定是否存在需要治疗的前列腺癌（临床意义重大的前列腺癌 1）最准确的血液测试。

与诊断方法相关的高成本预计会阻碍市场增长。

前列腺癌的诊断方法非常昂贵，而且由于癌症是一种无症状的疾病，因此需要在早期进行正确的诊断。廉价的诊断和不准确可能会阻碍全球市场。

行业分析

全球前列腺癌诊断市场根据各种行业因素（包括波特五力、监管分析、供应链分析、定价分析和技术进步）对市场进行了深入分析。

全球前列腺癌诊断市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 驱动因素：诊断测试的进步、政府加强癌症宣传活动
  • 限制因素
    • 阻碍因素：与诊断程序相关的高成本
  • 市场机会
  • 影响分析

第五章行业分析

• 波特五力分析
• 监管分析
• 供应链分析
• 定价分析
• 技术进步

第 6 章按测试类型

• 前列腺特异性抗原 (PSA) 检测
• 直肠指检 (DRE)
• 经直肠超声检查
• PCA3 检验
• 影像诊断
• 组织活检
• 其他

第 7 章，最终用户

• 医院和诊所
• 癌症研究所
• 诊断中心
• 其他

第 8 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 9 章竞争格局

• 主要发展和战略
• 公司份额分析
• 测试类型基准测试
• 值得关注的重点公司列表

第 10 章公司简介

• Myriad Genetics, Inc.
  • 公司概况
  • 测试类型组合和说明
  • 主要亮点
  • 财务摘要
• Genomic Health, Inc.
• Quanterix Corporation
• Metamark Genetics
• MDx Health
• Siemens Healthcare GmbH
• F. Hoffman-La Roche AG
• OPKO Health, Inc.

第11章 全球前列腺癌诊断市场-DataM

Market Overview

Prostate Cancer Diagnostics Market size was valued US$ 5.9 billion in 2021 and is estimated to reach US$ 8.4 billion by 2029, growing at a CAGR of 13.5% during the forecast period (2022-2029).

Prostate cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. It makes some of the fluid that is part of semen.

Almost all prostate cancers are adenocarcinomas. These cancers develop from the gland cells (the cells that make the prostate fluid added to the semen). Some other types of cancer that can start in the prostate include small cell carcinomas, neuroendocrine tumors, transitional cell carcinomas, and sarcomas. Prostate cancer can often be found early by testing prostate-specific antigen (PSA) levels in a man's blood or digital rectal exam (DRE). According to a study in the United States, the annual screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower prostate cancer's death rate.

Market Dynamics

The rising R&D initiatives in the prostate cancer diagnostic field and the recent regulatory approvals are driving the growth of the market.

Increasing advancements in diagnostic tests and rising government initiatives for cancer awareness are expected to drive market growth.

The continuous advancements in diagnostic for prostate cancer are driving the growth of the market globally. Some of the new test-launched by major players are:

In mar 2022, U.S.FDA approves Lu-PSMA-617 manufactured by Novartis. It is a radiopharmaceutical therapy that treats prostate cancer.

In Aug 2020, Garnet Health Medical Centre, offered an innovative technology that increases the ability that helps in early diagnosis and treatment of prostate cancer.

On December 29th, 2019, Anixa Biosciences, Inc. commercially launched the Cchek Prostate Cancer Confirmation test (Cchek PCC)- which utilizes artificial intelligence (AI), flow cytometry, and liquid-biopsy technology to detect prostate cancer was commercially launched. Once it becomes available, this test will reduce the need for expensive and invasive biopsy procedures to diagnose prostate cancer patients in certain patients.

In September 2019, a new and simple blood test was found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London. In combination with the current prostate-specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment. The new prostate cancer test (the Parsortix system from ANGLE plc) detects early cancer cells or circulating tumor cells (CTCs) that have left the original tumor and entered the bloodstream before spreading around the body. In July 2019, MDNA Life Sciences launched the Mitomic Prostate Test (MPTTM), the world's most accurate blood test, to determine whether a man does or does not have prostate cancer that requires treatment (clinically significant prostate cancer1).

High cost associated with diagnostic procedures is expected to hamper the market growth.

The prostate cancer diagnostic methods are very costly and cancer is an asymptomatic disorder that needs proper diagnosis in initial phase. Unaffordable diagnosis and Inaccuracy are likely to hamper the global market.

Industry Analysis

The global prostate cancer diagnostics market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Technology Advancement.

Segment Analysis

Prostate-specific antigen (PSA) test segment is expected to hold the largest market share in global prostate cancer diagnostics market

Prostate-specific Antigen (PSA) is a protein produced by prostate cells, and the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post-treatment to check if cancer relapses. PSA testing is an essential tool for detecting prostate cancer, which measures PSA's level in a man's blood. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people affected by prostate cancer. It has more market value in the countries with a high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer. The major players continuously innovate new PSA with advanced technology, which boosts the PSA test's growth in the prostate cancer diagnosis market. For instance, in February 2019, OPKO Health, Inc. received the U.S. Food and Drug Administration (FDA) approval for the point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the Claros 1 Analyzer. The product is indicated to quantitatively measure total PSA in whole blood from a fingerstick of blood collected by a healthcare professional. It is used in conjunction with a digital rectal exam to detect prostate cancer in men aged 50 years and older.

Geographical Analysis

North America region holds the largest market share in the global prostate cancer diagnostics market

North America is dominating the global prostate cancer diagnostics market, with the United States accounting as the major contributor to the market. Prostate cancer is one of the most common cancers in American men, and this is made apparent by the statistics surrounding it. It affects 1 out of eight men in U.S. After skin cancer it is the most common cancer in U.S. men. American Cancer Society estimated that in 2022 around 268,490 novel cases of prostate cancer will be detected. Some of the prostate cancers are aggressive but most of them grows slowly. The number of deaths increases year after year, making prostate cancer the second leading cause of cancer death in men in the United States. Hence, it is considered to have an early diagnosis of the condition.

The United States Preventive Services Task Force has analyzed the data from all reported prostate cancer screening trials, principally from the PLCO and ERSPC trials, and estimated that every 1,000 men ages 55 to 69 years screened every 1 to 4 years for 10 to 15 years. About 1 death from prostate cancer can be avoided. 120 men would have a false-positive test result that leads to a biopsy, and some men who get a biopsy would experience at least moderately bothersome symptoms from the biopsy. 100 men would be diagnosed with prostate cancer. Of those, 80 would be treated (either immediately or after a period of active surveillance) with surgery or radiation. At least 60 of these men would have a serious complication from treatment, such as erectile dysfunction and/or urinary incontinence.

Competitive Landscape

The growing awareness towards the availability of advanced cancer diagnostics technologies, especially in the emerging regions, is also likely to grow the prostate cancer diagnostics market. In addition to this, various governments' supportive initiatives across the globe would help boost the market growth.

Some of the major players dominating the market include Genomic Health, Inc., Quanterix Corporation, Metamark Genetics, Myriad Genetics, Inc., MDx Health, Siemens Healthcare GmbH, F. Hoffman-La Roche AG, OPKO Health, Inc., among others.

The key players are adopting several strategies such as product launches, partnerships, mergers and acquisitions, collaborations, finding a new market in their core competency to stay competitive in the market.

For instance,

• In June 2019, OPKO Health, Inc. (had submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore test. The 4Kscore test is a blood test used by health care professionals to assess a patient's risk of having aggressive prostate cancer after an abnormal prostate-specific antigen (PSA) test result and before a decision is made to perform a biopsy.
• In July 2019, MDNA Life Sciences launched the Mitomic Prostate Test (MPT) in the UK, the world's most accurate blood test to determine whether a man does or does not have prostate cancer that requires treatment.

Key Companies to Watch

Myriad Genetics:

Overview: Myriad Genetics, Inc. is American company that works in precision medicine and genetic testing. It was founded in 1991 and is headquartered in Utah, United States. It uses various proprietary technologies that helps doctors and patients understand the disease on the basis of genetics of human and gene role in treatment. With the help of this data and information new products are manufactured.

Product Portfolio:

Prolaris: It analyses the functional activity of genes that are involved in cancer cell proliferation and anticipates the cancer aggressiveness with the help of tissues that are collected during biopsy to confirm cancer diagnosis.

Key Developments: In Mar 2022, Myriad Genetics BRAC Analysis CDx test received FDA approval. It is used as an aid diagnostic that determine BRCA mutated variant.

The global prostate cancer diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1.1. Increasing advancements in diagnostic tests and rising government initiatives for cancer awareness
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost associated with diagnostic procedures
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Technology Advancements

6. By Test Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
  • 6.1.2. Market Attractiveness Index, By Test Type Segment
• 6.2. Prostate-specific antigen (PSA) Test
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Digital rectal exam (DRE)
• 6.4. Transrectal Ultrasound
• 6.5. PCA3Test
• 6.6. Diagnostic Imaging
• 6.7. Tissue Biopsy
• 6.8. Others

7. By End User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 7.1.2. Market Attractiveness Index, By End User Segment
• 7.2. Hospitals & Clinics
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Cancer Research Institutes
• 7.4. Diagnostic Centres
• 7.5. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 8.2.6. U.S.
  • 8.2.7. Canada
  • 8.2.8. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 8.3.6. Germany
  • 8.3.7. U.K.
  • 8.3.8. France
  • 8.3.9. Italy
  • 8.3.10. Spain
  • 8.3.11. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 8.4.6. Brazil
  • 8.4.7. Argentina
  • 8.4.8. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 8.5.6. China
  • 8.5.7. India
  • 8.5.8. Japan
  • 8.5.9. Australia
  • 8.5.10. Rest of Asia Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

9. Competitive Landscape

• 9.1. Key Developments and Strategies
• 9.2. Company Share Analysis
• 9.3. Test Types Benchmarking
• 9.4. List of Key Companies to Watch

10. Company Profiles

• 10.1. Myriad Genetics, Inc.
  • 10.1.1. Company Overview
  • 10.1.2. Test Type Portfolio and Description
  • 10.1.3. Key Highlights
  • 10.1.4. Financial Overview
• 10.2. Genomic Health, Inc.
• 10.3. Quanterix Corporation
• 10.4. Metamark Genetics
• 10.5. MDx Health
• 10.6. Siemens Healthcare GmbH
• 10.7. F. Hoffman-La Roche AG
• 10.8. OPKO Health, Inc.

LIST NOT EXHAUSTIVE

11. Global Prostate Cancer Diagnostics Market - DataM

• 11.1. Appendix
• 11.2. About Us and End User
• 11.3. Contact Us